Natural product-based therapy for p53-mutated human cancers: I3C increases tumor suppressor p53 homolouge TAp73 via down regulation of its target gene, 20/January/20145, 7.50 am

Natural product-based therapy for p53-mutated human cancers: I3C increases tumor suppressor p53 homolouge TAp73 via down regulation of its target gene, 20/January/20145, 7.50 am

Natural product-based therapy for p53-mutated human cancers: I3C increases tumor suppressor p53 homolouge TAp73 via down regulation of its target gene, 20/January/20145, 7.50 am 150 150

Idea Proposed/Formulated byDr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

CitationBoominathan, Natural product-based therapy for p53-mutated human cancers: I3C increases tumor suppressor p53 homolouge TAp73 via down regulation of its target gene, 20/January/20145, 7.50 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Significance: This study suggests, for the first time, that 13C, by decreasing the expression of its target gene, it may promote TAp73 tumor suppressor function  and inhibit the expression of cancer stem cell genes. Thereby, it may promote tumor suppression. Given that tumor suppressor p53 is mutated in more than 50% of different human cancers, this study suggests a therapeutic strategy as to how mutant p53 expressing human cancers can be cured; that is,  by activating its un-mutated homologous proteins, such as p73 in cancer cells. Thus, pharmacological formulations encompassing “13C or its analogues”  may be used to inhibit the progression of human tumors, including p53-mutated human tumors

Amount: $ 300

Undisclosed information: How 13C increases the stability and activity of p73α

Web: http://genomediscovery.org

Courtesy: When you cite drop us a line at info@genomediscovery.org

* Research cooperation